Nureca Limited (NSE:NURECA) filed a supplementary disclosure with the National Stock Exchange on 21 August 2026, providing mandated settlement details for a final GST rectification order received on 6 August 2026, which closed a tax demand for the period 2021-22 through an Input Tax Credit reversal of Rs 15,40,311.
Key Highlights
- The GST Department issued a final rectification order on 6 August 2026, disposing of a tax matter pertaining to the financial year 2021-22 under Section 161 of the CGST Act, 2017.
- The matter was resolved through reversal of Input Tax Credit amounting to Rs 15,40,311 (Rupees Fifteen Lakh Forty Thousand Three Hundred Eleven only), with the related GST demand subsequently dropped.
- The original demand arose from an order under Section 73(9) of the CGST Act, 2017 and Section 21 of the UT GST Act, 2017, issued in the form of Form DRC-07.
- The supplementary disclosure was filed by Company Secretary and Compliance Officer Nishu Kansal under Regulation 30(2) of the SEBI LODR Regulations, 2015, as additional detail to the earlier announcement of 7 August 2026.
About the Company
Nureca Limited (NSE:NURECA) is a Chandigarh-based consumer healthcare and wellness company that markets home healthcare devices and wellness products under its Dr. Trust and Trumom brands. Its product range spans digital blood pressure monitors, pulse oximeters, weighing scales, and mother and baby care accessories. The company is incorporated in Maharashtra with CIN L24304MH2016PLC320868 and operates in the consumer health devices segment across India.
Announcement in Detail
Nureca Limited filed supplementary information on 21 August 2026, as required under sub-para 20 of Para A of Part A of Schedule III of SEBI LODR, 2015. This followed the company's earlier Regulation 30 disclosure on 7 August 2026, which informed the exchange of the final rectification order received from the GST Department on 6 August 2026 at 12:39 PM.
According to Annexure A of the filing, the original demand was raised through a DRC-07 order under Section 73(9) of the CGST Act, 2017 and Section 21 of the UT GST Act, 2017. Nureca filed a rectification application under Section 161 of the CGST Act, 2017. The GST authority accepted the rectification, dropped the related demand, and closed the matter upon payment by way of ITC reversal of Rs 15,40,311.
Impact on Investors
Investors will note that the disclosed financial impact of this order is confined to the reversal of Input Tax Credit amounting to Rs 15,40,311, as explicitly stated in the filing. The company's own disclosure characterises this as the complete extent of the monetary impact on its financial and operational activities. The filing shows the GST demand for the 2021-22 tax period has now been formally closed by the relevant authority, with no further liability indicated in the document.
Shareholders will observe that this disclosure fulfils Nureca's compliance obligation under SEBI LODR Regulation 30(2), which requires listed entities to provide structured settlement particulars when a regulatory or tax order is received. The filing does not indicate any ongoing proceedings, penalties, or additional demands linked to this specific matter.
Sector / Market Context
GST-related rectification proceedings under Section 161 of the CGST Act, 2017 are a recognised compliance channel available to taxpayers who identify clerical or arithmetical errors in tax orders. The consumer healthcare devices segment in India, which includes home-use diagnostic equipment, has seen regulatory and compliance activity increase alongside the sector's growth since the pandemic period. SEBI's LODR framework requires listed companies to disclose tax and regulatory orders meeting prescribed thresholds, ensuring shareholders receive timely and structured information about proceedings that could carry a financial consequence, however small.